FDA approves artificial pancreas system
NEW YORK – The Food and Drug Administration has approved a commercial version of the Medtronic MiniMed 670G hybrid closed-loop system, an artificial pancreas system. "This announcement is a historic achievement for JDRF,” said Derek Rapp, CEO of the nonprofit dedicated to funding type 1 diabetes research. “After years of laying the ground work, this breakthrough is a testament to the reason JDRF exists—to help people with Type 1 diabetes lead better, safer, healthier lives while we continue on the path to cure and prevent the disease altogether.” Artificial pancreas systems are composed of insulin pumps, continuous glucose monitors and smart software to automate the delivery of the right amount of insulin at the right time. JDRF has supported the research and development of multiple systems across the globe.